Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9IX5

An agonist(compound 15n) of Thyroid Hormone Receptor B

This is a non-PDB format compatible entry.
Summary for 9IX5
Entry DOI10.2210/pdb9ix5/pdb
DescriptorThyroid hormone receptor beta, Nuclear receptor coactivator 2, 2-[(1-methoxy-7-naphthalen-2-yloxy-4-oxidanyl-isoquinolin-3-yl)carbonylamino]ethanoic acid, ... (4 entities in total)
Functional Keywordsnuclear receptor ligand-binding domain, agonist, transcription
Biological sourceHomo sapiens (human)
More
Total number of polymer chains2
Total formula weight31164.95
Authors
Yao, B.,Li, Y. (deposition date: 2024-07-26, release date: 2025-07-02, Last modification date: 2025-07-23)
Primary citationLi, Q.,Yao, B.,Zhao, S.,Lu, Z.,Wu, X.,Lu, Z.,Wu, T.,Li, J.,Chen, X.,Chen, Z.,Zhang, C.,Wu, D.,Zhang, Y.,Xiang, Q.,Li, Y.,Xu, Y.
Discovery of a Potent, Selective, and Multiple His435 Mutation-Sensitive Thyroid Hormone Receptor beta Agonist.
J.Med.Chem., 68:13471-13490, 2025
Cited by
PubMed Abstract: Beyond selectivity concerns for thyroid hormone receptor β (THR-β) agonists, intolerance to the His435 mutation remains a challenge. Following our previous study, we performed detailed modifications on the 7-position of isoquinoline, specifically targeting the hydrophobic region of the THR-β ligand-binding pocket (LBP). This led to the identification of compound , which showed potent THR-β agonistic activity (EC: 3.2 nM), moderately selectivity (∼10-fold), and good activation of multiple His435 mutants (EC: 134.2 nM to 515.5 nM). Co-crystal structures revealed that the introduction of small-volume groups into the hydrophobic pocket of THR-β almost did not significantly displace helix 11 or helix 3, explaining why can activate multiple His435 mutants simultaneously. Multiple experiments confirmed that exhibits excellent lipid metabolism, safety, and pharmacokinetic properties. Together, emerges as a potent, selective, and His435 mutation-sensitive THR-β agonist, offering potential for treating dyslipidemia, metabolic dysfunction-associated steatohepatitis (MASH), or resistance to thyroid hormone (RTH).
PubMed: 40539969
DOI: 10.1021/acs.jmedchem.5c00164
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.65 Å)
Structure validation

248942

PDB entries from 2026-02-11

PDB statisticsPDBj update infoContact PDBjnumon